News - Respiratory and Pulmonary, Boehringer Ingelheim

Filter

Popular Filters

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

Boehringer’s nintedanib slows IPF disease progression in Ph III trial

19-05-2014

Results from the Phase III INPULSIS trials, published on-line yesterday in the New England Journal of…

BiotechnologyBoehringer IngelheimnintedanibResearchRespiratory and Pulmonary

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

Boehringer Ingelheim files for expanded EU indication for Respimat

Boehringer Ingelheim files for expanded EU indication for Respimat

13-11-2013

German independent drug major Boehringer Ingelheim has submitted an applications to extend the indication…

Boehringer IngelheimEuropePharmaceuticalRegulationRespimatRespiratory and PulmonarySpiriva

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

COPD trial shows comparable efficacy in Boehringer's Spiriva Respimat and HandiHaler

09-09-2013

One of largest chronic obstructive pulmonary disease (COPD) trials conducted to date confirms comparable…

Boehringer IngelheimEuropePharmaceuticalResearchRespiratory and PulmonarySpiriva

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022

29-08-2013

The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

17-05-2013

German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care…

Boehringer IngelheimCombivent RespimatManagementPharmaceuticalProductionRespiratory and Pulmonary

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma patients

25-02-2013

German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III…

Boehringer IngelheimPharmaceuticalResearchRespiratory and PulmonarySpirivatiotropium

FDA advisory panel backs Boehringer's COPD drug olodaterol

30-01-2013

In a 15 to one vote with one abstension, the US Food and Drug Administration's Pulmonary-Allergy Drugs…

Boehringer IngelheimNorth AmericaolodaterolPharmaceuticalRegulationRespiratory and PulmonaryStriverdi Respimat

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment

01-11-2012

At its 3rd International Research & Development press conference, family-owned German drug major Boehringer…

afatinibBoehringer IngelheimnintedanibolodaterolOncologyPharmaceuticalProductionResearchRespimatRespiratory and Pulmonary

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Boehringer reveals new data on olodaterol and tiotropium combo at ERS

04-09-2012

German family-owned drug major Boehringer Ingelheim for the first time presented data from a Phase II…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and PulmonarySpirivatiotropium

Boehringer's Spiriva has advantages for patients with COPD, says IQWiG

29-08-2012

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD),…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and PulmonarySpiriva

Boehringer Ingelheim acquires Funxional products

24-07-2012

German family-controlled drug major Boehringer Ingelheim has entered an agreement to acquire the global…

Anti-Arthritics/RheumaticsBoehringer IngelheimFunxional TherapeuticsFX125LLicensingPharmaceuticalRespiratory and Pulmonarysomatotaxin

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Caelyx and Ceplene manufacturing should be moved, says EMA

18-03-2012

The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

COPD market to grow to more than $13.4 billion in 2020

19-12-2011

As a result of an expanding aging population, increases in drug treatment and the uptake of premium priced…

Boehringer IngelheimGlobalMarkets & MarketingolodaterolPharmaceuticalRespiratory and Pulmonarytiotropium

Boehringer Ingelheim’s Combivent Respimat Inhalation Spray OKed in USA to replace aerosol

09-10-2011

The US Food and Drug Administration has approved German independent drug major Boehringer Ingelheim’s…

Boehringer IngelheimCombiventNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top